STOCK TITAN

IGM Biosciences Inc - IGMS STOCK NEWS

Welcome to our dedicated news page for IGM Biosciences (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IGM Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IGM Biosciences's position in the market.

Rhea-AI Summary
Medivir's partner Tango Therapeutics receives FDA clearance for TNG348, a USP1 inhibitor for the treatment of HRD+ cancers. Phase 1/2 study to be initiated in 2024. Medivir entitled to milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
Medivir AB announces data on fostroxacitabine bralpamide's potential effect on hepatocellular carcinoma (HCC) to be presented at ILCA Annual Meeting. Preclinical results show fostrox's potential to enhance anti-tumor activity with kinase inhibitors such as Lenvima or sorafenib. Encouraging clinical results seen in ongoing phase 1b/2a study with fostrox + Lenvima. Expert Perspectives Webcast on HCC treatment challenges to be hosted on September 8th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
-
Rhea-AI Summary
IGM Biosciences CEO to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
conferences
Rhea-AI Summary
Medivir AB announces promising interim safety and efficacy data from its phase 1b/2a study of fostrox in combination with Lenvima® for advanced hepatocellular carcinoma (HCC) patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB to host key opinion leader webcast on HCC treatment landscape
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
Rhea-AI Summary
Medivir to present at the Erik Penser Bank Company Event on August 24, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences
Rhea-AI Summary
Medivir AB (MVIR) Announces Positive Preliminary Results from Phase 2a Study of Fostrox + Lenvima® in Advanced Hepatocellular Carcinoma Patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.37%
Tags
partnership
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
IGM Biosciences Inc

Nasdaq:IGMS

IGMS Rankings

IGMS Stock Data

538.49M
11.53M
35.23%
68.07%
8.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Mountain View

About IGMS

igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci